The fully closed-loop system represents a major advance in diabetes therapy. It connects an insulin pump with a continuous glucose monitor (CGM) to achieve full automation of insulin infusion, eliminating the need for patients to manually calculate carbohydrates or administer mealtime insulin injections.
In September 2025, at the Annual Meeting of the European Association for the Study of Diabetes (EASD), CamAPS HX — a fully closed-loop system developed by a team at the University of Cambridge — demonstrated excellent outcomes across multiple studies:
For patients with type 1 diabetes:After using the system, 26 adults with poor glycemic control showed significant improvements in blood glucose management. Trials in adolescents confirmed similar benefits, particularly enhancing freedom and confidence in exercise and social activities.
For patients with type 2 diabetes:Among 26 insulin users, the closed-loop system extended the time spent in the target glucose range by approximately 8 hours per day. For patients with concurrent renal failure, this improvement still reached 3.5 hours per day. Trial participants reported that frequent blood sampling and injections were no longer necessary, significantly improving quality of life and confidence in disease management.
This system is expected to deliver a more convenient, safe, and intelligent long-term glucose control experience for both type 1 and type 2 diabetes patients, reduce the burden of daily management, and lower the risk of diabetes-related complications.